---
title: "Weekly Recap | Merck this week, vaccine data hits but partner tumbles"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302952782.md"
description: "Merck (MRK) pulled back this week. As of 23 October after-hours, the stock traded at $145.30, down about 1.3% from the previous close. The weekly gain or loss and closing price are not provided in the server-side summary. In the final session, the stock touched a pre-market high of $147.60 before fading, then spent the day in a range between $143.41 and $145.44, a fading-from-high pattern. The S&P 500 slipped 0."
datetime: "2026-10-24T06:39:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302952782.md)
  - [en](https://longbridge.com/en/news/302952782.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302952782.md)
generator: "portal-rs"
---

# Weekly Recap | Merck this week, vaccine data hits but partner tumbles

## The Week

Merck (MRK) pulled back this week. As of 23 October after-hours, the stock traded at $145.30, down about 1.3% from the previous close. The weekly gain or loss and closing price are not provided in the server-side summary. In the final session, the stock touched a pre-market high of $147.60 before fading, then spent the day in a range between $143.41 and $145.44, a fading-from-high pattern. The S&P 500 slipped 0.47% for the week, while healthcare led defensives in Thursday’s session as investors turned cautious.

## Key Events

The dominant storyline was the Phase 3 readout for Merck and Moderna’s personalised mRNA cancer vaccine, INTerpath-001. Expectations had been building since 21 October, with rumours of a data leak emerging on 22 October. On 23 October, the companies confirmed the vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42%. The positive result was overshadowed by the embargo breach, which rattled investors and sent Moderna down roughly 20%. Separately, the European Commission approved the Keytruda and Padcev combination, extending Merck’s oncology portfolio.

## Analyst Ratings

As of 23 October, 27 brokers cover Merck: 14 rate it buy, 5 rate it overweight, and 8 rate it neutral, with no underweight or sell ratings. The consensus recommendation is buy. The consensus target price is $159.76, about 9.97% above the latest price. Targets range from $105.00 to $186.00, a wide spread that signals disagreement about valuation. Within its pharmaceutical peer group of 203 names, Merck ranks 4th in rating strength, placing it near the top of the sector.

## The Week Ahead

Merck reports fiscal Q3 2026 results on 29 October before the open. The market expects EPS of about $1.78 and revenue of about $17.3 billion, with guidance on the Keytruda franchise the key watch point. On the macro side, durable goods orders and consumer confidence data arrive early in the week, setting the risk tone for healthcare. The investigation into the cancer-vaccine data leak could also produce follow-up headlines.

## In Short

This week brought a European approval for a Keytruda combination and a positive Phase 3 readout for the cancer vaccine, yet the partner’s data leak and share-price plunge added volatility to the narrative. Brokers lean positive, with the consensus target above spot by about 10%, though the wide target range reflects genuine disagreement. The stock trades above 112x earnings, a demanding valuation. The questions ahead: whether Q3 results confirm growth in the core franchise, and whether the vaccine’s long-term recurrence data outweighs the short-term noise from the leak.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [What Is Merck (MRK) Betting On With Its $2.13 Billion KRAS Deal?](https://longbridge.com/en/news/300416193.md)
- [MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor](https://longbridge.com/en/news/300472171.md)
- [Darling Ingredients (DAR) Could Be 31% Undervalued On Reaffirmed Guidance And Product Launch](https://longbridge.com/en/news/302994330.md)
- [Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts](https://longbridge.com/en/news/302993182.md)
- [Keystone customers say breach exposed data the hardware wallet maker promised to delete](https://longbridge.com/en/news/302993239.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**